Physician profile
Haley Daniel
NPI 1205441532
$4,886.67
in general payments reported to CMS, 2019-2025
44 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $1,099 · 2023: $642 · 2024: $1,000 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,453.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,237.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $611.67 | 2021-2025 | Caplyta |
| Pfizer INC. | $347.02 | 2023-2025 | |
| Alkermes, INC. | $292.17 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $226.38 | 2024-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $198.97 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $169.39 | 2022 | |
| Indivior INC. | $138.27 | 2021-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $133.67 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Avanir Pharmaceuticals, INC. | $125.22 | 2021-2022 | |
| Novo Nordisk INC | $96.97 | 2021-2025 | |
| Tris Pharma INC | $94.05 | 2024-2025 | Dyanavel Xr |
| Gilead Sciences, INC. | $93.64 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $88.41 | 2021-2024 | Verquvo, Belsomra, Gardasil |
| Lilly USA, LLC | $86.28 | 2021-2024 | Mounjaro |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.